Nivolumab (Opdivo®). HTA ID: 23050

Assessment Status Rapid Review Complete
HTA ID 23050
Drug Nivolumab
Brand Opdivo®
Indication In combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥ 1%.
Assessment Process
Rapid review commissioned 01/08/2023
Rapid review completed 17/08/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab for this indication on the basis of the proposed price relative to currently available therapies.

The HSE has approved reimbursement following confidential price negotiations. May 2024